Carrier cell‐mediated delivery of oncolytic parvoviruses for targeting metastases
Open Access
- 22 January 2004
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 109 (5) , 742-749
- https://doi.org/10.1002/ijc.20013
Abstract
Over the last few years, naturally occurring or genetically manipulated oncolytic viruses gained increasing attention as novel therapeutics for cancer treatment. The present work provides proof of principle that an organotropic cell-based carrier system is suitable to deliver oncolytic parvoviruses to a tissue known to be a target for the formation of metastases. Carrier cells were inactivated by γ-irradiation after infection, which was found not to affect the production and release of parvoviruses that were capable of lysing cocultured target neoplastic cells. Although systemically administered parvovirus H-1 showed a pronounced therapeutic effect against the development of established Morris hepatoma (MH3924A) lung metastases, the carrier cell strategy offered a number of advantages. Infected carriers were able to sustain H-1 virus expression for 6 days in the lungs of rats affected by metastatic disease and to reduce the spreading of the virus to peripheral organs. Compared to direct virus injection, the carrier cell protocol led to an improved therapeutic effect (metastases suppression) and a lesser generation of virus-neutralizing antibodies. These data support the use of carrier cells to deliver oncolytic viruses and/or viral vectors locally in tumors and, more particularly, metastases.Keywords
This publication has 32 references indexed in Scilit:
- Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cellsCancer Gene Therapy, 2003
- The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to considerCancer Gene Therapy, 2002
- Construction and production of oncotropic vectors, derived from MVM(p), that share reduced sequence homology with helper plasmidsCancer Gene Therapy, 2002
- Potentiation of a recombinant oncolytic parvovirus by expression of ApoptinCancer Gene Therapy, 2001
- Endothelial cell–based systemic gene therapy of metastatic melanomaCancer Gene Therapy, 2001
- Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectorsCancer Gene Therapy, 2001
- A Cell-Based Drug Delivery System for Lung Targeting: II. Therapeutic Activities on B16-F10 Melanoma in Mouse LungsDrug Delivery, 2001
- Retrovirus‐elicited interleukin‐12 and tumour necrosis factor‐α as inducers of interferon‐γ‐mediated pathology in mouse AIDSImmunology, 1996
- Antineoplasic activity of parvovirusesJournal of Virological Methods, 1991
- Synergistic effect of coumadin and cytoxan in reducing lung metastasesJournal of Pediatric Surgery, 1986